Agonism Antagonism
Agonism Antagonism - Related Videos
01:14
Agonism and Antagonism: Quantification
0 Views •
2024
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response. To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
01:30
Combined Effects of Drugs: Antagonism
0 Views •
2025
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes. The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
12:09
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
0 Views •
Cited by 6 •
2019
This protocol describes the use of single chain MHC class I complexes to investigate molecular interactions in human CD8+ T cell activation: generation of engineered antigen presenting cells expressing single chain constructs, culture of human CD8+ T cell clone and T cell activation experiments.
10:13
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
0 Views •
Cited by 11 •
2017
Guanosine triphosphate (GTP) binding is one of the earliest events in G-Protein-Coupled Receptor (GPCR) activation. This protocol describes how to pharmacologically characterize specific GPCR-ligand interactions by monitoring the binding of the radio-labeled GTP analog, [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPγS), in response to a ligand of interest.
04:37
A Technique to Assess the Inhibitory Effect of Toxin Exposure on Miniature Excitatory Postsynaptic Currents (mEPSCs)
0 Views •
2025
The video demonstrates the electrophysiological analysis of embryonic stem cell-derived neurons after exposure to neurotoxins. Treating these neurons with botulinum neurotoxins reduces the frequency of spontaneous miniature excitatory post-synaptic currents, confirming inhibition of synaptic transmission.
FAQs
The balance between receptor activation and receptor blockade shapes the response observed as drug exposure changes. An agonist can increase signaling and therapeutic effect, whereas an antagonist can reduce or prevent that effect when an agonist is present. These relationships help explain differences in drug efficacy and why changing treatment or dose may alter clinical responses.
A partial agonist produces a limited receptor response while competing for access to the same receptor as a stronger agonist. By occupying receptors, it can reduce the stronger agonist’s ability to generate its full effect. This dual behavior makes partial agonists clinically important when treatment requires receptor stimulation without the maximal response associated with a stronger agonist.
Excessive receptor stimulation may contribute to adverse responses, while extensive receptor blockade may reduce the biological action of an endogenous ligand or therapeutic agonist. Recognizing which direction a drug shifts receptor signaling helps clinicians anticipate unwanted effects and evaluate whether symptoms may reflect overstimulation, insufficient activation, or an intended pharmacologic response.
Drug interactions can arise when one agent activates a receptor and another blocks access or signaling at that receptor. A competing partial agonist may also reduce the response produced by a stronger agonist. Assessing these relationships helps clinicians anticipate changes in therapeutic effect, particularly when treatments influence the same receptor system or when receptor blockade is introduced.
Treatment selection can incorporate the desired degree of receptor activation, the need to limit excessive signaling, and the expected efficacy of available agents. Clinicians use dose-response information and the distinction between full, partial, and blocked responses to match therapy with a patient’s therapeutic goals while anticipating adverse responses and interactions.
These principles provide context for pharmacologic decisions in pain, cardiovascular disease, and respiratory disorders, as well as other clinical conditions. In each setting, receptor activation or blockade can influence therapeutic effects and adverse responses. Understanding the underlying interaction supports interpretation of treatment outcomes and helps clinicians anticipate the consequences of overstimulation or reduced receptor signaling.